Aurobindo Pharma Limited (AUROPHARMA): research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Aurobindo Pharma Limited, explained in plain English.

• ▪Aurobindo Pharma Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
• ▪AUROPHARMA closed at ₹1,659.90 on 29 October 2026.
• ▪Over the past year the shares are up 49.3%, trading between ₹1,091.20 and ₹1,740.00.
• ▪Reported fundamentals show a net margin of 10.63%, debt to equity of 21.31.
• ▪Our transparent MaxGrade checklist scores it D (46/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
• ▪Annualised volatility over the past year is 26.26% with a maximum drawdown of -9.7% and a beta of 0.39 against NIFTY 50.
• ▪Recent coverage: Sona BLW, Solar Industries, Oracle, Aurobindo Pharma, CG Power: Midcap performers of 2026, price targets and more
• ▪Recent coverage: Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players
• ▪Recent coverage: Nifty's recovery or just another trap? Analysts split on market's future direction!

Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Biocon

Last traded values from 29 Oct 2026. Market opens at 9:15 IST.